MedTrace Logo

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

NCT07332182 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-01-12

No results posted yet for this study

Summary

The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location.

The evaluation will be performed through clinical, subjective and objective assessments.

Conditions

  • Osteochondral Lesions of the Knee Joint
  • Osteochondritis Dissecans (OCD)
  • Early Osteoarthritis

Interventions

DEVICE

osteochondral scaffold implant

three layered biomimetic osteochondral scaffold implant for osteochondral lesions of the knee

PROCEDURE

SSOC

Debridement

Sponsors & Collaborators

  • Fin-Ceramica Faenza Spa

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2031-04-30
Completion
2031-04-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07332182 on ClinicalTrials.gov